

HI 13TH

INTERNATIONAL
CONFERENCE

HAEMATOPOIESIS IMMUNOLOGY

BUDAPEST, HUNGARY

JUNE
3 & 4
2016



FINAL PROGRAM



VENUE:
HUNGARIAN ACADEMY
OF SCIENCES

Bone marrow immunology in minimal residual cancer

Moderator:

Prof George Janossy, LONDON, UNITED KINGDOM

Chairmen:

Prof Klaus Pantel, HAMBURG, GERMANY

Prof Jean-François Rossi, MONTPELLIER, FRANCE

Prof Nikolay Tupitsyn, MOSCOW, RUSSIA

www.imhaemo.ru

FRIDAY
JUNE
3RD

08.50 **Welcome address.** *Prof George Janossy, Prof Klaus Pantel, Prof Jean-Francois Rossi, Prof Lydia Campos, Prof Bruno Brando & Dr Catherine Alix-Panabières*

09.10 Who should be Involved in harmonizing MRD detection on solid tumours in PB and BM. *Andy Rawstron, Leeds, United Kingdom*

09.50 MRD IN ONCOHAEMATOLOGY

Chairman: Prof Lydia Campos

09.50 State of the art in acute myeloid leukemia minimal residual disease assessment. *Prof Lydia Campos, Saint-Étienne, France*

10.10 NGS for upfront characterization and assessment of treatment response in AML and MDS. *Prof Christian Thiede, Dresden, Germany*

10.30 Minimal residual disease in AML and the role of leukemia stem cells herein. *Prof Gerrit Jan Schuurhuis, Amsterdam, The Netherlands*

10.50 **Coffee break**

11.20 French myeloid database: relevant tool for anticipation the most frequent recurrent genetic abnormalitie and to improve the acute myeloid leukaemia diagnostic. *Dr Carmen Aanei, Saint-Étienne, France*

11.40 MINIMAL CANCER

Chairmen: Prof Klaus Pantel & Dr Catherine Alix-Panabières

11.40 Circulating and disseminated tumor cells: biology and clinical significance. *Prof Klaus Pantel, Hamburg, Germany*

12.10 Methods of CTC/DTC viability and function assessment. *Dr Catherine Alix-Panabières, Montpellier, France*

12.40 Molecular characterization of single tumor cells by NGS. *Anna Babayan, Hamburg, Germany*

12.50 Comparative analysis of multicolor flow cytometry and immunohistochemistry for the detection of disseminated tumour cells. *Eszter Szánthó, Debrecen, Hungary*

13.00 Selected poster presentations

13.00 Selection of DNA aptamers to human Interleukin-6 (hIL6). *Vera A. Spiridonova, Moscow, Russia*

13.05 Influence of c-MYC hyperexpression and RAS genes mutations on the disease prognosis and therapy response in multiple myeloma patients. *M. V. Nareyko, E. Y. Demidova, A. M. Sergeeva, V. L. Surin & L. P. Mendeleeva, Moscow, Russia*

13.10 **Lunch**

14.20 New data on DTC detection and monitoring by flow cytometry. *Olga Beznos, Moscow, Russia*

14.50 Flow Cytometry for the identification of rare cells. *Sara de Biasi, Modena, Italy*

15.20 IMMUNE THERAPY OF MRD

Chairmen: Prof Jean-Francois Rossi, Katherina Psarra & Prof Bruno Brando

15.20 Myeloid suppressor cells in hematological malignancies. *Katherina Psarra, Athens, Greece*

15.50 Myeloma and immune system: dangerous cross-roads. *Prof Bruno Brando, Legnano, Italy*

16.20 **Coffee break**

16.50 New frontiers in immunopathology: from dysimmune diseases to lymphoid malignancies. *Prof Jean-Francois Rossi, Montpellier, France*

17.20 Targets for immune therapy of minimal residual cancer. *Dr Alisa Petkevich, Moscow, Russia*

17.30 Mechanisms of chronic myelogenous leukemia cell death induced by a new inhibitor of Bcr-Abl tyrosine kinase. *Dr Ekaterina Kolotova, Moscow, Russia*

17.40 Cancer tissue microenvironment biomarker profiling assay. *Alex Chenchik, Cellecta*

20.00 **Evening with Budapest Operetta**

SATURDAY
JUNE
4TH

HI 13TH
INTERNATIONAL
CONFERENCE
**HAEMATOPOIESIS
IMMUNOLOGY**

09.00 HOW TO MAKE ACCESSIBLE FOR PRACTICE NEW DIAGNOSTIC APPROACHES CREATED BY SCIENCE

Seminars with WHO EXPERTS

Chairman: Dr Yana I. Gurkovskaya & Dr Farkhad Shamilov, Petrovax

09.00 Influence of polyoxidonium (immune adjuvant) on primary tumor and bone marrow in breast cancer patients.

Chairman: Dr Maria.E. Ilatovskaya

09.30 Perspectives of CTC and DTC HER2 detection for therapeutic targeting: questions and concerns.

10.00 Coffee break

Chairman: Prof Nikolay N. Tupitsyn, Moscow, Russia & Lubov Kuprova, Bioline

10.30 8-color Euroflow panels in MRD diagnosis in leukemias and lymphomas.

Chairmen: Prof Piarvin A. Zeynalova, Prof Timur T. Valiev & Mobil Akhmedov

11.00 CD20 in B-cell lymphomas: diagnosis and treatment of MRD. Immunochemotherapy with rituximab for pediatric patients with 3-4 Burkitt lymphoma risk group.
Timur Valiev, Moscow, Russia

11.30 YOUNG SCIENTIST SELECTED ORAL PRESENTATIONS

11.30 Antigen expression heterogeneity used for MRD monitoring in B-lymphoblastic leukemia.
Kateryna Vilchevska, Donetsk, Ukraine

11.40 Possibilities of overcoming drug resistance of blast cells in children with relapse of acute lymphoblastic leukemia. *Natalia Batmanova, Moscow, Russia*

11.50 Hospicell, a subset of bone marrow stromal cell regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line. *Nadia Benabou, Paris, France*

12.00 Role of telomerase mutation on myelodysplastic syndrome and other haematopoietic disorders.
Sushama Jose Shyam, Brno, Czech Republic

12.10 **Take home message.**
End of the congress.

GENERAL INFORMATION

Location:

Hungarian Academy
of Sciences,
Széchenyi István tér 9,
1051 Budapest, Hungary

Organization: com.co

Com&Co, Étienne Jarry
15, Bd Grawitz,
13016 Marseille, France
Tel.: (+33) 4 91 09 70 53
Fax: (+33) 4 96 15 33 08
ejarry@comnco.com

HI 13TH

INTERNATIONAL
CONFERENCE
HAEMATOPOIESIS
IMMUNOLOGY

PARTNERS



Non-commercial Partnership
EQUAL RIGHT TO LIFE



NPO
PETROVAXPHARM

Medicines of Future Today